EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients

Robert Zeiser, Halvard Bönig, Elena Osswald, Uwe Pichlmeier, Ann-Kristin Möller, Michael Tribanek, Maria Lazarou-Wild, Renate von der Weth, Lisa-Marie Pfeffermann, Peter Bader

Transfusion Medicine and Hemotherapy · 16.02.2026 · 53 (3) · 134-144

DOI: 10.1159/000550469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 16.02.2026. Verfasst von Robert Zeiser und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg im Breisgau, Germ…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acute graft-versus-host disease (aGvHD) is a potentially life-threatening complication that can occur following allogeneic haematopoietic stem cell transplantation. Although corticosteroids remain the standard first-line therapy, a considerable number of patients fail to respond adequately, leading to significant morbidity.

Methods

Mesenchymal stromal cells (MSCs) are being investigated as a therapeutic option in this setting due to their immunomodulating and tissue-regenerative properties. Two ongoing clinical trials – IDUNN (NCT04629833) and BALDER (NCT06075706) – are assessing the role of the innovative product MSC-FFM/MC0518 in managing steroid-refractory aGvHD (SR-aGvHD). In parallel, a dedicated surveillance programme is collecting long-term efficacy and safety data to inform clinical use beyond the controlled trial environment.

Conclusion

The IDUNN and BALDER trials will deliver definitive evidence on the efficacy and safety of MC0518 in SR-aGvHD and may shape future therapeutic strategies.

Schlagwörter

Stichwörter der Autor:innen

Acute graft-versus-host diseaseAllogeneic haematopoietic stem cell transplantationMC0518MSC-FFMMesenchymal stromal cellsSteroid-refractory acute graft-versus-host disease

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg im Breisgau, Germany.
  • Faculty of Medicine, Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.
  • German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt am Main, Germany.
  • medac GmbH, Wedel, Germany.
  • Department of Pediatrics, Division of Stem Cell Transplantation and Immunology, Goethe University Frankfurt, Frankfurt am Main, Germany.

Zitieren

APA

Zeiser, R., Bönig, H., Osswald, E., Pichlmeier, U., Möller, A. K., Tribanek, M., Lazarou-Wild, M., von der Weth, R., Pfeffermann, L. M., & Bader, P. (2026). Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients. Transfusion Medicine and Hemotherapy, 53(3), 134-144. https://doi.org/10.1159/000550469

Vancouver

Zeiser R, Bönig H, Osswald E, Pichlmeier U, Möller AK, Tribanek M, et al. Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients. Transfusion Medicine and Hemotherapy. 2026;53(3):134-144. doi:10.1159/000550469

BibTeX
@article{Zeiser2026,
  author = {Zeiser, Robert and Bönig, Halvard and Osswald, Elena and Pichlmeier, Uwe and Möller, Ann-Kristin and Tribanek, Michael and Lazarou-Wild, Maria and von der Weth, Renate and Pfeffermann, Lisa-Marie and Bader, Peter},
  title = {Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients},
  journal = {Transfusion Medicine and Hemotherapy},
  year = {2026},
  volume = {53},
  number = {3},
  pages = {134--144},
  doi = {10.1159/000550469}
}
Kostenlos starten →